Opinion|Videos|March 1, 2025
Impact of GPP Triggers and Flares on a Patient’s Physical and Mental Health
Panelists discuss the physical and mental health challenges of generalized pustular psoriasis (GPP), common flare triggers, the varying severity of flares, and the importance of timely treatment to prevent severe complications.
Advertisement
Video content above is prompted by the following:
Episodes in this series
- How do you talk to your patients with GPP about their physical and mental health?
- What are some common triggers of GPP flares? How do you discuss identifying and managing triggers with your patients?
- Discuss the physical impact of GPP flares on a patient. How can GPP flares differ in severity from patient to patient and even from flare to flare?
- What are some severe complications that can arise from GPP flares, and how important is it to treat GPP flares in a timely manner?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
2
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
3
Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5